MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
9.99
-0.65
-6.11%
Pre Market: 9.99 0 0.00% 07:00 05/08 EDT
OPEN
10.91
PREV CLOSE
10.64
HIGH
11.12
LOW
9.91
VOLUME
200
TURNOVER
0
52 WEEK HIGH
25.07
52 WEEK LOW
9.66
MARKET CAP
859.61M
P/E (TTM)
-2.5912
1D
5D
1M
3M
1Y
5Y
1D
Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results
Simply Wall St · 1h ago
New Analyst Forecast: $SNDX Given 'Sector Perform' Rating
NASDAQ · 11h ago
Syndax publishes AUGMENT-101 trial data in Blood
TipRanks · 13h ago
Syndax Pharma Publishes Data From Pivotal Phase 2 Portion Of AUGMENT-101 Trial Of Revumenib In Patients With R/R mNPM1 Acute Myeloid Leukemia In Blood
Benzinga · 15h ago
Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call
TipRanks · 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 1d ago
Syndax Pharmaceuticals Price Target Raised to $17.00/Share From $16.00 by Scotiabank
Dow Jones · 1d ago
Syndax Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Dow Jones · 1d ago
More
About SNDX
More
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Recently
Symbol
Price
%Change

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.